According to Zhitong Finance APP, Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Yifan Pharmaceutics, has signed exclusive agreements with Accendatech and Tianjin Accendatech respectively. The exclusive agreements stipulate that Accendatech will grant Yifan Pharmaceutics a sublicensable and irrevocable exclusive right and license within the cooperation area for the active ingredient of its independently developed target product, dimethylamino micaceous lactone fumarate monohydrate. Yifan Pharmaceutics can independently use the licensed intellectual property rights to develop, produce, and commercialize the target product within the cooperation area. Simultaneously, Yifan Pharmaceutics is granted exclusive priority negotiation rights for the production and commercialization of the target product for other indications within the cooperation area.

Yifan Pharmaceuticals is required to pay Accendatech an initial payment of RMB100 million, a cornerstone investment of RMB100 million or a milestone payment of RMB50 million (choose one), a tiered share of net sales revenue, and a share of sublicense revenue outside of China (if any).

Regarding the basic information of the target product, ACT001, developed by Accendatech, is a Class 1 innovative drug with a novel mechanism. Over the past eight years, it has undergone multiple clinical trials in China, the United States, and Australia, targeting various indications including small cell lung cancer brain metastases and glioma. In January 2025, ACT001 received 'Breakthrough Therapy' designation from the National Medical Products Administration for its small cell lung cancer brain metastasis indication and successfully commenced Phase III clinical trials. ACT001 achieves local tumor control and prolonged survival by inhibiting the NF-κB and STAT3 signaling pathways in related cells within the cancer lesion tissue microenvironment, reducing tumor cell DNA repair capacity, and exhibiting a dual synergistic effect with radiotherapy, chemotherapy, and immunotherapy.

The announcement stated that the target product targets the clinically urgent and treatment-scarce area of small cell lung cancer with brain metastases. By introducing an innovative anti-tumor drug that has entered late-stage clinical trials, the company can effectively supplement its oncology pipeline and avoid the high investment and time costs required for independent research and development from scratch.

Disclaimer: This content is created by a Tencent platform creator and does not represent the views or positions of this site.